MGC - The Forgotten Updates, page-10

Opinion: considerably undervalued at 6 cents

Reasons: Market cap of other MM stocks compared to MXC progress / achievements, revenue growth and market recognition via derma has been a real success - potential buyout target, the co. entering critical period post GMP for pharma - Cannepil = cash on the table, Europe market is beckoning, large and years post legalisation. The neurologist coming onto staff is critical - all signs, in spite of the scars (VC the biggest gash) and churn along the way, point firmly to u n d e r v a l u e d